Want to see FBLG full AI Analyst Report?
FibroBiologics, Inc. (FBLG) Stock Statistics & Valuation Metrics
Total Valuation
FibroBiologics, Inc. has a market cap or net worth of $6.19M. The enterprise value is $3.89M.
- Market Cap
- $6.19M
- Enterprise Value
- $3.89M
Share Statistics
FibroBiologics, Inc. has 6,658,193 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 6,658,193
- Owned by Insiders
- 97.77%
- Owned by Institutions
- 1.83%
Financial Efficiency
FibroBiologics, Inc.’s return on equity (ROE) is -3.03 and return on invested capital (ROIC) is -194.36%.
- Return on Equity (ROE)
- -3.03
- Return on Assets (ROA)
- -1.94
- Return on Invested Capital (ROIC)
- -194.36%
- Return on Capital Employed (ROCE)
- -2.12
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.24M
- Employee Count
- 15
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of FibroBiologics, Inc. is -0.15. FibroBiologics, Inc.’s PEG ratio is 0.22.
- PE Ratio
- -0.15
- PS Ratio
- 0.00
- PB Ratio
- 0.76
- Price to FCF
- -0.42
- Price to Operating Cash Flow
- -0.24
- PEG Ratio
- 0.22
Income Statement
In the last 12 months, FibroBiologics, Inc. had revenue of 0 and earned -18.65M in profits. Earnings per share was -8.35.
- Revenue
- 0
- Gross Profit
- -832.00K
- Operating Income
- -16.65M
- Pretax Income
- -18.65M
- Net Income
- -18.65M
- EBITDA
- -17.61M
- Earnings Per Share (EPS)
- -8.35
Cash Flow
In the last 12 months, operating cash flow was -14.79M and capital expenditures -6,000, giving a free cash flow of -14.80M billion.
- Operating Cash Flow
- -14.79M
- Free Cash Flow
- -14.80M
- Free Cash Flow per Share
- -3.92
Dividends & Yields
FibroBiologics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -238.95%
- Earnings Yield
- -516.95%
Stock Price Statistics
- Beta
- 0.68
- 52-Week Price Change
- -88.28%
- 50-Day Moving Average
- 1.32
- 200-Day Moving Average
- 2.32
- Relative Strength Index (RSI)
- 36.67
- Average Volume (3m)
- 212.92K
Important Dates
FibroBiologics, Inc. upcoming earnings date is Nov 17, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Jul 31, 2026
- Next Earnings Date
- Nov 17, 2026
- Ex-Dividend Date
- ―
Financial Position
FibroBiologics, Inc. as a current ratio of 3.61, with Debt / Equity ratio of 39.15%
- Current Ratio
- 3.61
- Quick Ratio
- 3.61
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.14
- Interest Coverage Ratio
- -81.61
Taxes
In the past 12 months, FibroBiologics, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
FibroBiologics, Inc. EV to EBITDA ratio is -0.24, with an EV/FCF ratio of -0.28.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.24
- EV to Free Cash Flow
- -0.28
- EV to Operating Cash Flow
- -0.28
Balance Sheet
FibroBiologics, Inc. has $3.52M in cash and marketable securities with $1.46M in debt, giving a net cash position of $2.05M billion.
- Cash & Marketable Securities
- $3.52M
- Total Debt
- $1.46M
- Net Cash
- $2.05M
- Net Cash Per Share
- $0.31
- Tangible Book Value Per Share
- $1.23
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for FibroBiologics, Inc. is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $6.00
- Price Target Upside
- 545.16% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 22.10%
Scores
- Smart Score
- ―
- AI Score
- 41